References
- Alter C. Google Seeks Human Guinea Pigs for Health Project [Internet]; 2014 [cited 2015 Nov 7]. Available from: http://time.com/3045429/google-baseline-study-human-health/#3045429/google-baseline-study-human-health/: TIME magazine.
- Li A, Meyre D. Jumping on the train of personalized medicine: A primer for non- geneticist clinicians: Part 3. Clinical applications in the personalized medicine area. Curr Psychiatry Rev. 2014;10(2):118–132.
- McNeil C. NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst. 2015;107:7.
- Flores M, Glusman G, Brogaard K, et al. P4 medicine: how systems medicine will transform the healthcare sector and society. Per Med. 2013;10(6):565–576.
- 23andme. 23 and me [Internet]; www.23andme.com. [cited 2015 Oct 5]. Available from: https://www.23andme.com/en-ca/reviews/?utm_source=google&utm_medium=cpc&utm_campaign=CA_Search-Branded&utm_term=can_onepager&utm_content=23c_Search_Paid_Brand&gclid=CLPSi8SN3MkCFYMDaQod7NkLfw.
- Yousef GM. Personalized medicine in kidney cancer: learning how to walk before we run. Eur Urol. 2015;68(6):1021–1022.
- Kontos EZ, Viswanath K. Cancer-related direct-to-consumer advertising: a critical review. Nat Rev Cancer. 2011;11(2):142–150.
- Bollinger JM, Green RC, Kaufman D. Attitudes about regulation among direct-to-consumer genetic testing customers. Genet Test Mol Biomarkers. 2013;17(5):424–428.
- Pasic MD, Samaan S, Yousef GM. Genomic medicine: new frontiers and new challenges. Clin Chem. 2013;59(1):158–167.
- Roberts NJ, Vogelstein JT, Parmigiani G, et al. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012;4(133):133ra58.
- Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. Jama. 2006;296(2):212–215.
- Green RC, Berg JS, Grody WW, et al., et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15(7):565–574.
- Diamandis EP, Li M. The side effects of translational omics: overtesting, overdiagnosis, overtreatment. Clin Chem Lab Med. 2016;54(3):389–396.
- Yousef GM. miRSNP-based approach identifies a miRNA that regulates prostate-specific antigen in an allele-specific manner. Cancer Discov. 2015;5(4):351–352.
- Yousef GM. Personalized cancer genomics: the road map to clinical implementation. Clin Chem. 2012;58(4):661–663.
- Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317–319.
- Rafiq M, Ianuale C, Ricciardi W, et al. Direct-to-consumer genetic testing: A systematic review of European guidelines, recommendations, and position statements. Genet Test Mol Biomarkers. 2015;19(10):535–547.
- Rittenhouse H, Blase A, Shamel B, et al. The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem. 2013;59(1):32–34.
- Autier P, Boniol M, Gavin A, et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. Bmj. 2011;343(jul28 1):d4411.
- Schrijver I, Aziz N, Farkas DH, et al., et al. Opportunities and challenges associated with clinical diagnostic genome sequencing: a report of the association for molecular pathology. Journal Molecular Diagnostics: JMD. 2012;14(6):525–540.
- Bombard Y. Translating personalized genomic medicine into clinical practice: evidence, values, and health policy. Genome National Research Council Canada = Génome Conseil National De Recherches Canada. 2015;58(12):491–497.
- Collins F. Has the revolution arrived? Nature. 2010;464(7289):674–675.
- Joyner MJ, Paneth PN. Seven questions for personalized medicine. Jama. 2015;314(10):999–1000.
- Diamandis EP. The hundred person wellness project and google’s baseline study: medical revolution or unnecessary and potentially harmful over-testing? BMC Med. 2015;13(1):5.